Table 4.
Univariate meta-regression and subgroup analysis for the primary outcome (histological response).
| Covariate | κ | Sensitivity (95% CI) | p value | Specificity (95% CI) | p value |
|---|---|---|---|---|---|
| Study design characteristics | |||||
| Region | |||||
| Asian | 1 | 0.73 (0.41–1.00) | 0.87 | 0.79 (0.54–1.00) | 0.94 |
| Western | 5 | 0.68 (0.51–0.85) | 0.77 (0.64–0.90) | ||
| Study design | |||||
| Prospective | 5 | 0.66 (0.50–0.83) | 0.32 | 0.79 (0.71–0.87) | 0.48 |
| Post-hoc | 1 | 0.81 (0.58–1.00) | 0.57 (0.38–0.76) | ||
| Histological score | |||||
| NI | 4 | 0.74 (0.64–0.84) | 0.03* | 0.81 (0.64–0.98) | 0.61 |
| GS | 2 | 0.56 (0.40–0.72) | 0.75 (0.49–1.00) | ||
| MES ⩾ 1 | |||||
| ⩾70% | 3 | 0.61 (0.42–0.79) | 0.11 | 0.76 (0.57–0.96) | 0.59 |
| <70% | 3 | 0.77 (0.61–0.93) | 0.81 (0.61–1.00) | ||
| FC test characteristics | |||||
| FC assay | |||||
| ELISA | 3 | 0.75 (0.57–0.94) | 0.71 | 0.73 (0.56–0.90) | 0.26 |
| Not ELISA or unclear | 3 | 0.62 (0.41–0.84) | 0.81 (0.65–0.96) | ||
| Intervals between fecal sampling and endoscopy/number of patients | |||||
| Within 7 days/⩾100 | 4 | 0.67 (0.46–0.87) | 0.40 | 0.71 (0.56–0.87) | 0.07* |
| Over 7 days or unclear/<100 | 2 | 0.80 (0.56–1.00) | 0.90 (0.77–1.00) | ||
| FC cut-off value | |||||
| ⩽100 µg/g | 4 | 0.65 (0.47–0.84) | 0.38 | 0.80 (0.67–0.93) | 0.91 |
| >100 µg/g | 2 | 0.77 (0.53–1.00) | 0.71 (0.49–0.92) | ||
CI, confidence interval; ELISA, enzyme-linked immunosorbent assay; FC, fecal calprotectin; GS, Geboes score; MES, Mayo endoscopic score; NI, Nancy Index.
*
p < 0.10.